- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05930041
Injured Submucosal Arteries After CSP for 10-19 mm Nonpedunculated Colorectal Polyps.
August 5, 2026 updated by: Akira Horiuchi, Showa Inan General Hospital
The Presence of Injured Submucosal Arteries After Cold Snare Polypectomy(CSP) is Lower Than That of Conventional Hot Snare Endoscopic Mucosal Resection (HS-EMR) for 10-19 mm Nonpedunculated Colorectal Polyps.
Cold polypectomy has the advantages of simple operation, less time-consuming and fewer complications.
Guidelines have recommended cold snare polypectomy (CSP) to resect small polyps sized <9 mm.
CSP was designed to improve the complete resection rate and reduce adverse events.
Investigators hypothesize that CSP is better than conventional hot snare endoscopic mucosal resection (HS-EMR) in the presence of injured submucosal arteries detected in the submucosal layer for 10-19 mm nonpedunculated colorectal polyps, resulting in lower delayed bleeding after CSP of 10-19 mm nonpedunculated colorectal polyps.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Cold polypectomy has the advantages of simple operation, less time-consuming and fewer complications.
Guidelines have recommended cold snare polypectomy (CSP) to resect small polyps sized <9 mm.
CSP was designed to improve the complete resection rate and reduce adverse events.
Investigators hypothesize that CSP is better than conventional hot snare endoscopic mucosal resection (HS-EMR) in the presence of injured submucosal arteries detected in the submucosal layer for 10-19 mm nonpedunculated colorectal polyps, resulting in lower delayed bleeding after CS-EMR of 10-19 mm nonpedunculated colorectal polyps.
The primary outcome measure was the presence of injured submucosal arteries detected in the submucosal layer.
The secondary outcomes included immediate bleeding and the frequency of delayed bleeding requiring endoscopic treatment within 2 weeks after polypectomy.
Immediate bleeding was defined as spurting or oozing which continued for more than 30 seconds.
Study Type
Interventional
Enrollment (Actual)
124
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nagano
-
Komagane, Nagano, Japan, 399-4117
- Showa Inan General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- at least one polyp sized 10-19 mm (Paris classification Is or IIa) revealed by endoscopic examination.
Exclusion Criteria:
- American Society of Anesthesiologists status class 3 or above
- poor bowel preparation (Boston Bowel Preparation Scale <6 points)
- endoscopic features indicating submucous infiltration or malignancy
- oral anticoagulants,or antiplatelet agents, or known blood coagulation disorders, or bleeding tendency
- a history of colorectal resection
- emergent colonoscopy (haemodynamic instability and/or continued active gastrointestinal bleeding and/or requiring intensive care patients)
- inflammatory bowel disease, familial polyposis and colorectal cancer
- pregnancy or lactation
- severe cardiopulmonary dysfunction, cirrhosis, chronic kidney disease, other malignant tumours or severe infectious diseases.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: HS-EMR
|
Either HS-EMR is performed for 10-19 mm nonpedunculated colorectal polyps.
|
|
Experimental: CSP
|
Either CSP is performed for 10-19 mm nonpedunculated colorectal polyps.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the presence of injured submucosal arteries detected in the submucosal layer.
Time Frame: 1 day
|
the presence of injured submucosal arteries detected in the submucosal layer.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Delayed bleeding
Time Frame: 14 days
|
The frequency of delayed bleeding requiring endoscopic treatment within 2 weeks after polypectomy.
|
14 days
|
|
Immediate bleedling
Time Frame: 1 day
|
The frequency of Immediate bleeding which was defined as spurting or oozing which continued for more than 30 seconds.
|
1 day
|
|
One-year adenoma recurrence rate
Time Frame: 1 year
|
Adenoma recurrence rate at the resection site at one-year follow-up
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2023
Primary Completion (Actual)
December 31, 2024
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
June 25, 2023
First Submitted That Met QC Criteria
June 25, 2023
First Posted (Actual)
July 5, 2023
Study Record Updates
Last Update Posted (Actual)
August 10, 2026
Last Update Submitted That Met QC Criteria
August 5, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSP/HSEMR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.